Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/302% below fair value
$396.74−1.34 (-0.34%)
Close on Nov 19, 2026Market cap $9.17BP/E –Yield –
Madrigal Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2024 it was $173.90M.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $173.90M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $132.74M | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
See a number that looks wrong?